2EyesVision
Invest in the revolution of personalized vision surgery
2EyesVision is transforming how patients choose their lenses before surgery. With unique technology, a booming market and a world-class scientific team, we are seeking strategic partners to scale globally.
2EyesVision was born as a spin-off of the Spanish National Research Council (CSIC) with a clear mission: to change the way patients experience vision before undergoing cataract or presbyopia surgery.
With our commercially available simulator, SimVis Gekko2, doctors and patients can now test different intraocular lenses in real-time before making a surgical decision. This ability to personalize treatment is redefining modern ophthalmology.
With the premium market growing rapidly and a validated, proprietary technology, we are at a pivotal stage of international expansion. We are looking for strategic investors who share our vision and want to lead this global transformation with us.
Why SimVis Gekko2 is a game-changer in the premium vision market
SimVis Gekko2 is not a simulation on screen or a virtual reality demo. It is a real-world visual experience that allows patients to test how they would see with different intraocular lenses—before surgery. This unique approach bridges the gap between medical prescription and patient understanding, making SimVis Gekko2 a disruptive tool in a market that demands personalization.
With SimVis Gekko2, surgeons can:
- Fine-tune IOL selection with precision
- Compare trifocal and EDOF lenses in real time
- Test monovision setups
- Measure perceived visual function
- Manage expectations effectively
- Educate patients like never before
This level of customization is currently unavailable with any other tool, and that’s exactly where the commercial and clinical opportunity lies.
2EyesVision created SimVis Gekko™
For the first time, patients can see the real world through binocular presbyopic and cataract premium corrections before treatment
SimVis Gekko2 is an advanced technology that allows patients to experience the real world through binocular premium presbyopic corrections before intraocular lens implantation or presbyopic laser refractive surgery
Fine-tuning IOL
Trifocals
EDOF
Mix&Match
Testing premium vision
SimVis Gekko2 is not virtual reality but a real visual experience that allows patients to see the real world with a wide field of view. You can take advantage of SimVis Gekko2 to:
Measure defocus curves
Test monovision
Measure perceived visual function
Manage expectations
Educate patients
In the premium market, one size does NOT fit all!
Patients can easily understand different corrections
Each patient is better suited to a different lens. There is no one lens that is the best option for everyone. This is why the visual simulator SimVis Gekko experience before surgery is so important.
What is #SimVisGekko?
Huge unmet need & market opportunity
Our focus lies in addressing highly prevalent ocular conditions such as presbyopia, which affects nearly 100% of the population above 45 years old, and cataracts, whose prevalence is estimated to double with 230 million people affected by 2050
Cataracts
Opacifications in the eye due to natural process of aging
of the population over the age of 75
million surgeries in 2024
Presbyopia
Hard to see near objects due to natural process of aging
of the population over the age of 45
billion people in 2024
Presbyopia is a non-preventable, gradual and irreversible eye condition with loss of the ability to focus on nearby objects. The worldwide presbyopia population is estimated to reach 3,3 billion by 2050, growing at 52% mainly due to population growth.
On the other hand, a cataract is the partial or complete loss of transparency in the crystalline lens or its capsule. Cataract is the most common cause of blindness and is often related to ageing. The only effective treatment for cataract is surgical lens extraction and implantation of an intraocular lens.
The worldwide cataract population is estimated to reach nearly 230 million by 2050, growing at 102% mainly due to ageing population growth.
Premium market: A growing untapped opportunity
Currently, there are more than 5 million premium cataract procedures globally, representing a remarkable rising trend in the ophthalmology sector and it is the fastest growing segment for cataract and refractive surgery.
The Premium segment includes more than 100 intraocular lens designs, each one having different impact on patient’s vision, making it difficult to manage patient’s expectation appropriately.
At an additional cost out-of-pocket for the patient of $4.800 in the US, the Global Premium industry revenue is estimated at USD 2,2 billion with USD 12,1 billion incremental provider fees, representing an untapped and huge market opportunity for 2EyesVision to capture.
2EyesVision designs and produces a visual simulation tool to help eyecare professionals perform their best care anywhere. With 2EyesVision, eyecare professionals can increase their revenue and reputation while improving patient’s satisfaction.
Identified and Potential Exit Strategy
We have identified a clear exit strategy for Investors through an M&A transaction with already identified potential buyer segments:
The ophthalmology sector is a “hot spot” for bigger companies that want to include the latest technology available to complement their product portfolios and offer the best eyecare experience for their patients. There are remarkable recent transactions that demonstrates this strong interest by leading ophthalmology companies worldwide:
Clinicians stories
Ophthalmologists and optometrists from all over the world tell us about their first-hand experience with SimVis technology.
Expert insights: Ophthalmologists and optometrists reviewing SimVis Gekko
As seen in
Additional information
OUR PARTNERS AND RESOURCES
Let's explore the vision of the future together!
Contact US